Lợi ích của hóa trị bổ trợ trong ung thư vú ba lần âm tính giai đoạn T1b và T1c không có hạch bạch huyết

Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical Oncology/College of american pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013 Hammond ME et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795 Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(Suppl 1):27–40 Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424 Siegel RL et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33 Haffty BG et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657 Dent R et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434 Johansson ALV et al (2019) Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer 144(6):1251–1261 Chaudhary LN (2020) Early stage triple negative breast cancer: management and future directions. Semin Oncol 47(4):201–208 Anampa J, Makower D, Sparano JA (2015) Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 13:195 Lu JY, Alvarez Soto A, Anampa JD (2022) The landscape of systemic therapy for early stage triple-negative breast cancer. Expert Opin Pharmacother 23(11):1291–1303 Bonadonna G et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294(8):405–410 Early Breast Cancer Trialists’, Collaborative G et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444 Autier P, Boniol M (2018) Mammography screening: a major issue in medicine. Eur J Cancer 90:34–62 Vaz-Luis I et al (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32(20):2142–2150 Bao J et al (2019) Outcomes in patients with small node-negative invasive breast cancer. Breast J 25(4):638–643 Ho AY et al (2012) Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 118(20):4944–4952 Lai HW et al (2011) Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol 37(1):18–24 An X et al (2020) Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: a single-center study and a meta-analysis of the published literature. Cancer 126:3837–3846 Gradishar WJ et al (2022) Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(6):691–722 Curigliano G et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast Cancer 2017. Ann Oncol 28(8):1700–1712 Steenbruggen TG et al (2020) Adjuvant chemotherapy in small node-negative triple-negative breast cancer. Eur J Cancer 135:66–74 Hanrahan EO et al (2007) Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25(31):4952–4960 Stuber T et al (2017) Are there breast Cancer patients with node-negative small tumours, who do not benefit from Adjuvant systemic therapy? Oncology 92(6):317–324 Migdady Y et al (2013) Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes. Breast 22(5):793–798 Lan T et al (2021) The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis. J Cancer 12(1):10–17 Fasano GA et al (2022) Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat 192(1):163–173 Houvenaeghel G et al (2014) Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. Ann Oncol 25(3):623–628 Leon-Ferre RA et al (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167(1):89–99 Pistelli M et al (2013) Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. Anticancer Res 33(6):2737–2742 Ren YX et al (2019) Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer. Breast 43:97–104 Zhai Z et al (2020) Evaluation of adjuvant treatments for T1 N0 M0 triple-negative breast Cancer. JAMA Netw Open 3(11):e2021881 Doll KM, Rademaker A, Sosa JA (2018) Practical guide to Surgical Data sets: Surveillance, Epidemiology, and end results (SEER) database. JAMA Surg 153(6):588–589 Griggs JJ et al (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 30(25):3058–3064 Liu YL et al (2019) Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 178(2):379–388 Du ZL et al (2020) Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database. Breast Cancer Res Treat 183(2):429–438 Tao L et al (2019) Breast Cancer mortality in older and younger patients in California. Cancer Epidemiol Biomarkers Prev 28(2):303–310 Prakash O et al (2020) Racial disparities in Triple negative breast Cancer: a review of the role of Biologic and non-biologic factors. Front Public Health 8:576964 Newman LA et al (2006) Meta-analysis of survival in african american and white american patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24(9):1342–1349 Chlebowski RT et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97(6):439–448 Welch HG et al (2016) Breast-Cancer tumor size, overdiagnosis, and Mammography Screening effectiveness. N Engl J Med 375(15):1438–1447 Jasra S, Anampa J (2018) Anthracycline Use for early stage breast Cancer in the modern era: a review. Curr Treat Options Oncol 19(6):30 Early Breast Cancer Trialists’ Collaborative Group. Electronic address, b.o.c.o.a.u. and G. Early Breast Cancer Trialists’ Collaborative, Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet (2023) 401(10384): p. 1277–1292